Altchem Ltd's Form 4 filing

RVL Pharmaceuticals plc (RVLP) · filed Oct 23, 2023

Accession no.: 0001752864-23-000002
Filed: Oct 23, 2023, 1:06 PM ET
Trade date: Oct 19-20, 2023
Filing delay: 4 days
Rule 10b5-1 plan: Not checked

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market sales total $580.1K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Altchem LtdCIK 0001752864	10% Owner
Orbit Co-Invest A-1 LLCCIK 0001753129	10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Oct 19, 2023	Ordinary Shares	SSaleDisposed	−9,363,760	$0.0461^F1	−$431,669.34	9,700,000	Direct
Oct 20, 2023	Ordinary Shares	SSaleDisposed	−4,758,899	$0.0312^F2	−$148,477.65	4,941,101	Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

The price reported in Column 4 is the average execution price. These shares were sold in multiple transactions at prices ranging from $0.0400 to $0.0580, inclusive. The reporting person undertakes to provide RVL Pharmaceuticals plc, any security holder of RVL Pharmaceuticals plc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

The price reported in Column 4 is the average execution price. These shares were sold in multiple transactions at prices ranging from $0.0300 to $0.0373, inclusive. The reporting person undertakes to provide RVL Pharmaceuticals plc, any security holder of RVL Pharmaceuticals plc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)